- Trial phase
- Phase 3
- Time to market
- Phase 3 primary completion is expected in 2029. If successful, regulatory filing and potential approval would likely follow in 2030-2031 at the earliest.
- Why 4/10
- No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled within the next ~12 months. The Phase 3 primary completion is expected in 2029. The drug is partnered with Roche, so Prothena's share-price sensitivity to this single asset is moderated by its other pipeline programs and cash position.
The next major catalyst for prasinezumab is the Phase 3 primary completion expected in 2029, which is years away. In the nearer term, watch for any interim data updates from Roche's Phase 3 program or additional exploratory analyses presented at medical conferences. Prothena's nearer-term binary catalyst is the moponetug Phase 2 data readout expected in 1H 2027.
Price Chart
Executive Summary
Prasinezumab is an investigational anti-alpha-synuclein monoclonal antibody for early-stage Parkinson's disease, developed by Prothena (PRTA) in partnership with Roche. The Phase IIb PADOVA study (586 patients) missed its primary endpoint in December 2024, but Roche decided to advance the drug into Phase III development in June 2025 based on numerical trends and exploratory signals suggesting possible benefit, particularly in patients with rapidly progressing disease. Phase 3 trials are underway with primary completion expected in 2029, meaning no near-term binary catalyst. Prothena has $272.2M cash, no debt, and a market cap around $421M. The stock trades near its 52-week low of $7.73, with a major insider buying aggressively in recent months.
How It Works
Prasinezumab is an intravenous monoclonal antibody designed to target and help clear clumps of alpha-synuclein protein in the brain. In Parkinson's disease, alpha-synuclein misfolds and aggregates into toxic clumps (Lewy bodies) that damage neurons. Prasinezumab aims to bind to these aggregated proteins and tag them for removal by the immune system, potentially slowing disease progression.
Trial Status
Prasinezumab is in Phase 3 development for early-stage Parkinson's disease, following the Phase IIb PADOVA study (586 patients) that missed its primary endpoint but showed numerical trends. Roche initiated Phase 3 in mid-2025. Prothena's Q3 2026 earnings report indicates Phase 3 primary completion is expected in 2029. Partner presentations at AD/PD 2026 conference in March 2026 covered clinical updates on prasinezumab.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 primary completion expected in 2029 (no near-term binary catalyst)
- Potential interim data or exploratory analyses presented at medical conferences
- Moponetug Phase 2 data readout expected in 1H 2027 (separate Prothena program)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PROTHENA CORP PUBLIC LTD CO 8-K PRTA ·Originating report